Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode (original) (raw)

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia

Steffen Moritz, D. Naber, Prof. Dr. Martin Lambert

Acta Psychiatrica Scandinavica, 2005

View PDFchevron_right

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response

Isabell Heuser

Psychiatry Research, 2008

View PDFchevron_right

Psychotic symptoms in patients with medical disorders

Rajnish Mago

Current Psychiatry Reports, 2004

View PDFchevron_right

Effect of Antipsychotic Withdrawal on Negative Symptoms in Schizophrenia

Stephan Arndt

Neuropsychopharmacology, 1994

View PDFchevron_right

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Glenn Phillips

Patient Preference and Adherence, 2011

View PDFchevron_right

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

Ronald Marcus

The International Journal of Neuropsychopharmacology, 2003

View PDFchevron_right

Does Combined Antipsychotic Treatment Provide Better Control on Symptoms in Patients with Schizophrenia than the Monotherapy?

Volkan Sahiner

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 2016

View PDFchevron_right

Treatment Guidelines for Patients with Schizophrenia or Psychotic Disorder who are Hospitalized in a Psychiatry Clinic

Dr. Hülya Ensari

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 2014

View PDFchevron_right

Current State of Psychopharmacology, Psychotherapies and Other Interventions in Mental Health Problems and Disorders

José Bertolín-Guillén

Advances in Image and Video Processing, 2021

View PDFchevron_right

Common Mental Disorders: Integration of Psychotherapy as a Treatment in Addition to the Use of Psychotropic Drugs

Nayla Saadi Senna

International Journal of Sciences, 2024

View PDFchevron_right

Antipsychotic Drugs

Melissa Piasecki

Encyclopedia of Substance Abuse Prevention, Treatment, & Recovery

View PDFchevron_right

Clozapine versus other atypical antipsychotics for schizophrenia

Claudia Asenjo-Lobos

Cochrane Database of Systematic Reviews, 2010

View PDFchevron_right

Tranquilising agitated mentally ill patients: intramuscular haloperidol plus promethazine reduces need for additional medication or medical attention compared to olanzapine

Prathap Tharyan

Evidence-based Mental Health, 2008

View PDFchevron_right

Rational Polypharmacy in Psychiatry

Sai Krishna Tikka

Evidence-based Strategies in Herbal Medicine, Psychiatric Disorders and Emergency Medicine, 2015

View PDFchevron_right

Today’s psychopharmacological treatments: results, problems, new perspectives

Selim Kiliç

Bulletin of Clinical Psychopharmacology, 2012

View PDFchevron_right

Second Generation Long-Acting Antipsychotics in the Treatment of Bipolar Disorder: A Clinical Viewpoint

Alessandro Carano

Bipolar Disorder, 2018

View PDFchevron_right

Health-Related Quality of Life in People Living with Psychotic Illness and Factors Associated with Its Variation

Vaughan Carr

Value in Health, 2018

View PDFchevron_right

Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?

Nele Vriendt

BMC Psychiatry, 2012

View PDFchevron_right

P.2.020 Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia

M. Bilici

European Neuropsychopharmacology, 2003

View PDFchevron_right

2nd Schizophrenia International Research Society Conference

Renan Souza

Schizophrenia Research, 2009

View PDFchevron_right

Mental Health Patient-Reported Outcomes and Experiences Assessment in Portugal

Niek Klazinga

International Journal of Environmental Research and Public Health, 2022

View PDFchevron_right

Proposing a causal pathway for health-related quality of life in people with psychotic disorders

Vaughan Carr

Journal of Psychiatric Research, 2021

View PDFchevron_right

Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression

Judith D Weissman

Psychiatry Research, 2012

View PDFchevron_right

Effectiveness of Pharmacotherapy for Severe Personality Disorders

Theo Ingenhoven

The Journal of Clinical Psychiatry, 2009

View PDFchevron_right

The positive impact of cariprazine in schizophrenia treatment management – case report

Diana-Elena Nistor

Romanian Journal of Psychiatry & Psychotherapy, 2022

View PDFchevron_right